1392150-29-6

Basic information

• Product Name: 5-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine
• Synonyms: 5-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine
• CAS NO: 1392150-29-6
• Molecular Weight: 276.245
• Mol File: 1392150-29-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine(1392150-29-6)
• EPA Substance Registry System: 5-(3,5-difluorobenzyloxy)-1H-pyrazolo[3,4-b]pyridin-3-amine(1392150-29-6)

Safety Data

• Hazardous Substances Data: 1392150-29-6(Hazardous Substances Data)

Upstream product

• 298204-74-7 5-(methyloxy)pyridine-3-carbonitrile 
• 1392150-30-9 5-(3,5-difluorobenzyloxy)nicotinonitrile 
• 1392150-31-0 3-cyano-5-(3,5-difluorobenzyloxy)pyridine 1-oxide 
• 1392150-33-2 2-chloro-5-(3,5-difluorobenzyloxy)nicotinonitrile 
• 152803-24-2 5-hydroxypyridine-3-carbonitrile 

Relevant articles and documents

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.